Search

A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults

No currently licensed and available vaccine has been shown to provide broad protection against endemic MnB disease.

4CMenB vaccine and its role in preventing transmission and inducing herd immunity

Vaccination is the most effective method of protecting people from invasive meningococcal disease (IMD). Of all the capsular groups, B is the most common cause of invasive meningococcal disease in many parts of the world. Despite this, adolescent meningococcal B vaccine programs have not been implemented globally, partly due to the lack of evidence for herd immunity afforded by meningococcal B vaccines.

Teens with diabetes cope with the additional burden of CV protection

ACE inhibitors and statins are well tolerated in teenagers with Type 1 Diabetes but more evidence is required to demonstrate whether they are effective

Diabetes link to deadly diseases

New research led by The Kids' PhD student Matthew Cooper has found that some children with T1D have an increased risk of developing vascular diseases.

Expansion of the Human Phenotype Ontology (HPO) knowledge base and resources

The Human Phenotype Ontology is a standardized vocabulary of phenotypic abnormalities used by researchers, clinicians, informaticians and electronic health record systems

A phase 3, multicenter, randomized, double-blind study to evaluate the interchangeability of V114, a 15-valent pneumococcal conjugate vaccine, and PCV13 with respect to safety, tolerability, and immunogenicity in healthy infants (PNEU-DIRECTION)

Pneumococcal disease (PD) remains a major health concern globally. In children, pneumococcal conjugate vaccines (PCVs) provide protection against PD from most vaccine serotypes, but non-vaccine serotypes contribute to residual disease. V114 is a 15-valent PCV containing all 13 serotypes in Prevnar 13™ and public health important serotypes 22F and 33F. This phase 3 study evaluated safety and immunogenicity of mixed PCV13/V114 regimens using a 3 + 1 dosing schedule when changing from PCV13 to V114 at doses 2, 3, or 4. 

Michael Slee

Research Associate PLAYCE

The Koolungar (Children) Moorditj (Strong) Healthy Skin Project Part I: Conducting First Nations Research in Pediatric Dermatology

Integrating First Nations knowledge systems and Western research methodologies recognizes the strength, experience, and insight of First Nations peoples in addressing health issues in their communities. In research, this includes projects being led by First Nations Elders and peoples, including First Nations researchers in the team, and collecting data in ways that reflect First Nations ways of knowing, being, and doing.

Wideband Absorbance Among Aboriginal and/or Torres Strait Islander and Non-Aboriginal Children With Suspected Otitis Media Living in an Australian Urban Area

Otitis media (OM) is a significant health concern, particularly among Aboriginal and/or Torres Strait Islander children who experience one of the highest rates of OM globally. This study aimed to evaluate the use and differences of wideband absorbance at ambient pressure (WBA) among urban Aboriginal and/or Torres Strait Islander and non-Aboriginal children with suspected OM based on standard tympanometry.

Clinical utility of the parent listening and understanding measure (PLUM) for Aboriginal and/or Torres Strait Islander and non-Aboriginal children with otitis media living in urban areas

This study evaluated the clinical utility of the Parent Listening and Understanding Measure (PLUM) questionnaire as a potential screening tool for otitis media (OM) and associated hearing loss in Aboriginal and/or Torres Strait Islander and non-Aboriginal children.